Journal
BLOOD ADVANCES
Volume 1, Issue 12, Pages 772-778Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2016001883
Keywords
-
Categories
Funding
- McMaster University
- Hamilton Health Sciences RFA Strategic Initiative Program
- Department of Oncology, McMaster University
- Canadian Institutes of Health Research
Ask authors/readers for more resources
Ibrutinib therapy was associated with an increased risk of bleeding in previous trials. In this systematic review and meta-analysis of published trials including patients treated with ibrutinib, the relative risk (95% confidence interval [CI]) of overall bleeding was significantly higher in ibrutinib recipients (2.72 [1.62-6.58]), but major bleeding did not show a significant difference (1.66 [0.96-2.85]). The incidences (95% CI) of major bleeding and any bleeding were 3.0 (2.3-3.7) and 20.8 (19.1-22.1) per 100 patient-years, respectively. This analysis is limited by reporting bias from variable ascertainment of bleeding and lack of allocation concealment in some studies and differing exposures between groups, leading to potential overestimation of event rates in the ibrutinib group.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available